Key Highlights
- Evolve Rat and Evolve Mouse, EPA-exempt soft baits regulated as minimum-risk pesticides under FIFRA Section 25(b), generated approximately 85% of SenesTech's $493,000 in first-quarter 2026 revenue, according to the company's May 12, 2026 release and Form 10-Q.
- Gross margin reached a company-record 68.6% in the first quarter of 2026, but net loss widened to $2.1 million on severance and legal costs, leaving $6.8 million in cash and short-term investments as of March 31, 2026.
- SenesTech has executed two reverse stock splits since November 2023 and drawn more than $117 million from equity issuance since inception, a dilution pattern that has repeatedly rebuilt the share count between splits.
- (SNES) is whether pilots in named cities convert into recurring contracts.
SenesTech, Inc. (NASDAQ:SNES) has spent two decades trying to replace rat poison with rodent birth control, and its Evolve soft-bait line now drives most of its sales. The company's first-quarter 2026 results, released May 12, 2026, show record gross margin alongside a widening net loss, a shrinking cash pile, and a share count reshaped by two reverse stock splits since late 2023.
A Small Pest-Control Innovator Draws a Second Look
Rodents cause billions of dollars in annual damage worldwide, and most control programs still rely on poisons that harm non-target wildlife. SenesTech, Inc., based in Surprise, Arizona, has built its business around fertility control products that reduce rodent reproduction rather than killing rodents outright. Its newer product family, Evolve, has grown from a 2024 launch into the majority of revenue, and recent releases describe pilots with named cities, new distribution partners and international registrations. None of that has made SenesTech self-funding; it remains a sub-$1-million-a-quarter revenue company leaning on capital markets to stay open.
From ContraPest to Evolve: SenesTech's (SNES) Two-Product Fertility Control Business
SenesTech's original product, ContraPest, is a liquid bait targeting the reproductive systems of male and female Norway and roof rats. It is registered as a general-use pesticide in all 50 states and D.C., and requires a restricted-use license in Connecticut, per the company's Form 10-Q for the quarter ended March 31, 2026. Evolve, the newer and now-dominant line, is a soft bait built around cottonseed oil. Evolve Rat launched in January 2024 and Evolve Mouse followed that May; both qualify as minimum-risk pesticides under FIFRA Section 25(b), exempting them from federal EPA registration, though some states require separate registration.
SenesTech is authorized to sell Evolve Rat in 48 states and territories and Evolve Mouse in 37. Since 2024, it has signed international distribution agreements covering the Netherlands, Australia and New Zealand, Singapore, the UAE, Hong Kong and, most recently, Bermuda through a June 2026 deal with Animal and Garden House, plus deployments in the U.S. Virgin Islands and Belize. Domestically, it named Bradley Caldwell, Inc. a U.S. distributor in June 2025 and Wilco Distributing an agriculture partner in 2024; products also sell through Amazon, Walmart, Home Depot's website and TractorSupply.com.
Catalyst Watch: Municipal Pilots and Agricultural Trials Test Evolve's Reach
The most closely watched catalyst for SenesTech, Inc. (SNES) is whether pilots in named cities convert into recurring contracts. The New York City Council approved a rat contraception pilot in October 2024, and the company's May 2026 earnings release said the 12-month pilot was expected to conclude that month, without disclosing renewal terms. Baltimore adopted Evolve in January 2025 and expanded use after a successful pilot, per a June 2025 release; SenesTech has also described deployments in Chicago since April 2025, a Swampscott, Massachusetts pilot from October 2025, and "increased municipal deployment activity" in Washington, D.C., without naming a contract there. A July 2026 release described an estimated 80% decline in observed rodent activity at a 400-acre Texas farm using an agricultural bait station protecting irrigation lines. None of these releases disclosed dollar figures for the underlying orders.
First-Quarter 2026: Record Margin, Wider Loss
SenesTech reported net revenue of $493,000 for the quarter ended March 31, 2026, up 2% from $485,000 a year earlier, which it attributed to Evolve growth offsetting a ContraPest decline and a temporary $157,000 hit from moving Amazon sales management in-house. Direct-to-consumer revenue rose 42% to $194,000, subscription revenue rose 44% to $56,000, and B2B revenue rose 57% to $298,000. Gross profit rose 8% to $338,000, lifting gross margin to a company-record 68.6% from 64.5%. SG&A rose 31% to $2.0 million on $213,000 of litigation costs and $230,000 of severance tied to a transition that saw Michael Edell named President and CEO in May 2026. Net loss widened to $2.1 million from $1.7 million, and adjusted EBITDA loss was $1.6 million versus $1.5 million a year earlier.
Cash, Dilution and the Reverse-Split Pattern
As of March 31, 2026, SenesTech held $6.8 million in cash, down from $7.6 million at year-end 2025; management expects this, plus anticipated revenue, to fund operations into Q3 2027. Since inception, SenesTech has drawn net proceeds of $117.2 million primarily from equity and warrant sales, against just $8.3 million in cumulative product sales (showing how dependent it has been on capital markets rather than operations. That dependence shows in the share count. SenesTech effected a 1-for-12 reverse split in November 2023, cutting shares from roughly 5.9 million to about 492,000, and a 1-for-10 split in July 2024, cutting shares from about 5.1 million to roughly 514,000.
Warrant exercises and offerings) $1.1 million in March 2025, $4.4 million in July 2025 and $6.3 million in August 2025: rebuilt the count to 5.3 million by May 2026, with weighted-average shares jumping from 1.3 million in Q1 2025 to 5.26 million in Q1 2026. Nasdaq listing compliance remains a recurring risk factor in company filings.
Where Growth Could Come From Next
SenesTech's near-term plan centers on deepening direct-to-consumer e-commerce after completing its in-house Amazon transition, with an April 2026 monthly e-commerce record of $146,000; expanding B2B and municipal channels; and pursuing international registrations opportunistically. It also redesigned packaging, targets a third-quarter e-commerce relaunch, and hired Jack Karabees as Executive Vice President of Sales in June 2026.
What Could Go Wrong
SenesTech's central risk is scale: quarterly revenue in the hundreds of thousands of dollars against a net loss exceeding $2 million means it must grow sales sharply or keep raising capital, and it has relied overwhelmingly on the latter. The reverse-split history signals repeated pressure on Nasdaq listing compliance, and further dilution remains possible if the cash runway shortens. Municipal and international deployments are mostly pilots or early-stage agreements without disclosed revenue, so conversion into durable sales is unproven. State-by-state registration adds complexity, and severance and legal costs tied to the management change could recur.
Outlook
The upside case rests on Evolve's non-lethal positioning resonating with municipalities and sensitive markets like Bermuda, alongside real gross-margin gains and an accelerating direct-to-consumer channel. The base case is modest, uneven revenue growth while the company burns cash and periodically taps equity markets, consistent with its stated runway into Q3 2027. The downside case involves slower contract conversion, losses outpacing revenue, and further dilutive financing that erodes existing shareholders' stakes.
Conclusion
SenesTech, Inc. (SNES) has built a genuinely different approach to an old pest-control problem, and Evolve is gaining named distribution partners and municipal pilots across multiple continents. But the first-quarter 2026 numbers ($493,000 in revenue, a $2.1 million net loss, and a share count reshaped by a two-reverse-split history) show a company that has not yet proven its commercial model can outrun its cash burn. Whether Evolve becomes a durable standard for humane rodent control or stays a niche product funded by recurring share issuance will define SenesTech's next several quarters.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.



_11_13_2026_19_02_15_269119.jpg)


Please wait processing your request...